Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab

Aranzazu Jauregui-Amezaga
Michael Somers
Heiko De Schepper
Elisabeth Macken

Department of Gastroenterology, Universitair Ziekenhuis Antwerp, University of Antwerp, Antwerp, Belgium

Abstract: The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn’s disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit of the cytokines interleukin-12 and interleukin-23. Consequently, the Th1 and Th17 inflammatory responses are inhibited. Ustekinumab has been recently approved for its use in patients with Crohn’s disease. Its efficacy and safety was initially proved in patients with psoriasis and psoriatic arthritis. More recently, three Phase III trials have confirmed its efficacy in patients with Crohn’s disease refractory to anti-tumor necrosis factor therapy. This biologic agent appears safe, with no increased risk of infectious or malignant complications, and a low immunogenic profile.

Keywords: ustekinumab, interleukin-12, interleukin-23, biologic therapy, inflammatory bowel disease, Crohn’s disease

Introduction

Crohn’s disease (CD) is a chronic inflammatory disease that causes transmural inflammation of the gastrointestinal wall. The presence of chronic active inflammation can induce the development of bowel damage, such as stenosis and fistula. Multiple therapies are nowadays available for inducing and/or maintaining remission in CD: corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), anti-tumor necrosis factor (anti-TNF) agents (infliximab, adalimumab, certolizumab pegol), and anti-integrin agents (natalizumab, vedolizumab). But their limited efficacy in some patients (primary nonresponders), loss of response over time (secondary nonresponders), or the occurrence of adverse events has led to the development of new molecules that target different inflammatory pathways.

Ustekinumab (Stelara®; Janssen Biotech Inc., Horsham, PA, USA) is a monoclonal antibody which targets the common p40 subunit of the cytokines interleukin (IL)-12 and IL-23. The use of ustekinumab was initially approved for the treatment of patients with plaque psoriasis (2009) and psoriatic arthritis (2013). Recently, the US Food and Drug Administration together with the European Medicines Agency has also approved the use of ustekinumab for the treatment of moderate-to-severe active CD in patients aged ≥18 years. In the case of Europe, ustekinumab can be administered to patients who are refractory and/or intolerant to anti-TNF agents, or to those who have medical contraindications to such therapies.
Mechanism of action and pharmacokinetics of ustekinumab

Multiple cytokines participate in the activation of the immune response in patients with immune-related diseases. Naïve CD4+ T cells can differentiate into four main subsets: Th1, Th2, Th17, and regulatory T cells. The IL-12 family includes different cytokines that are key mediators of the inflammatory response, such as IL-12, IL-23, IL-27, and IL-35.4-6 They are produced by the antigen presenting cells – dendritic cells and macrophages – during intestinal inflammation in patients with CD.

IL-12 and IL-23 are heterodimeric cytokines which are closely related, but have different roles. Both cytokines contain a p40 chain. IL-12 and IL-23 contain the unique subunits p35 and p19, respectively (Figure 1). IL-12 binds to the IL-12 receptor, which is a heterodimeric receptor formed by IL-12R-β1 and IL-12R-β2. IL-12 is essential for generating immunity to intracellular pathogens. It is involved in the differentiation of naïve CD4+T cells into Th1 cells, which results in the production of interferon gamma and tumor necrosis factor alpha (TNF-α) by natural killer and T cells. IL-23 binds to a heterodimeric complex receptor consisting of IL-12 receptor (IL-12R-β1) and IL-23 receptor complex (IL-23R). This receptor confers to IL-23 a specific intracellular signaling that promotes autoimmune inflammation, with consequent lymphocyte activation. In the presence of IL-23, the activated T cells acquire a Th17 phenotype, with the overproduction of IL-17 and other proinflammatory molecules such as IL-1, IL-6, and TNF-α. Both cytokines activate Janus kinase and Signal Transducer and Activator of Transcription downstream signaling molecules.7

Ustekinumab is a fully human IgG1 monoclonal antibody that targets the common p40 subunit of the cytokines IL-12 and IL-23 (IL-12/23p40). Thus, the blockage of this p40 protein prevents the binding of IL-12 and IL-23 to their specific receptor complexes on the surface of NK and T cells, inhibiting both Th1 and Th17 inflammatory responses. Its efficacy in intestinal inflammation has been demonstrated in the experimental models of colitis.8-13

Figure 1 Schematic representation of IL-12 and IL-23 with their receptors and downstream signaling pathways.

Abbreviations: IL, interleukin; STAT, Signal Transducer and Activator of Transcription.
Patients with psoriasis were the first-in-human population who received ustekinumab and in whom pharmacokinetics was primarily studied.\(^{14}\) The pharmacokinetic characteristics of ustekinumab were comparable to those of human endogenous IgG1. Intravenous (IV) and subcutaneous (SC) administration of ustekinumab showed an extended elimination half-life of 3 weeks. Both administration routes had linear pharmacokinetic profiles. The highest concentration was detected in the serum 7–14 days after SC administration. Ustekinumab exhibited comparable pharmacokinetic profiles across the dermatologic, rheumatic, gastrointestinal, and central nervous system indications studied to date. No significant drug interaction has been described.

In patients with CD, an initial IV induction dose based on body weight (6 mg/kg ustekinumab) is recommended, followed by SC ustekinumab administration. The first SC dose of 90 mg should take place at week 8 after the IV dose. Afterward, dosing every 12 weeks is recommended. Patients who do not show adequate response at week 8 (after the first SC dose) may receive a second SC dose at this time. Patients who lose response on dosing every 12 weeks may benefit from an increase in dosing frequency to every 8 weeks. Patients may subsequently be dosed every 8 weeks or every 12 weeks according to clinical judgment. No pharmacokinetic data are available either in elderly or pediatric patients with impaired renal or hepatic function.

**Ustekinumab in psoriasis and psoriatic arthritis**

**Psoriasis**

Psoriasis was the first-in-human indication of ustekinumab. This indication was based on Phase III trials conducted in North America and Europe (PHOENIX 1, PHOENIX 2, and ACCEPT), Korea and Taiwan (PEARL), and Japan (Japanese trial) that assessed the efficacy of ustekinumab in patients with moderate-to-severe psoriasis from different ethnic populations.\(^{15–19}\) The primary endpoint of these trials was the proportion of patients achieving improvement of at least 75% in psoriasis area and severity index at week 12. This index is a measure of overall psoriasis severity and extension of the lesions.

In the PHOENIX 1 trial, 766 patients were randomly assigned to receive ustekinumab 45 or 90 mg (at weeks 0 and 4, and then every 12 weeks) or placebo (at weeks 0 and 4, with subsequent crossover to ustekinumab at week 12); 171 (67%) patients receiving ustekinumab 45 mg, 170 (66%) receiving ustekinumab 90 mg, and 8 (3%) receiving placebo achieved the primary endpoint.\(^{15}\) Patients receiving the monoclonal antibody presented statistically significant differences in response rates, compared to placebo: 64% of patients with ustekinumab 45 mg and 63% of patients with ustekinumab 90 mg (\(p<0.0001\)). Long-term response at week 40 was also assessed with a new randomization at week 40 to maintenance ustekinumab versus placebo. Response was also better in those patients who continued the treatment with ustekinumab (\(p<0.0001\)).

The PHOENIX 2 trial included 1,230 patients who were randomly assigned to receive ustekinumab 45 or 90 mg (at weeks 0 and 4, then every 12 weeks) or placebo.\(^{16}\) Dose intensification was assessed in partial responders, as these patients were re-randomized at week 28 to continue dosing every 12 weeks or escalate to dosing every 8 weeks. Treatment with ustekinumab every 12 weeks was effective for most patients: 273 (67%) patients receiving ustekinumab 45 mg, 311 (76%) patients receiving ustekinumab 90 mg, and 15 (4%) receiving placebo achieved the primary endpoint. Difference in response rate was 63% for the 45 mg group and 72% for the group of 90 mg (\(p<0.0001\)). After the dosing intensification to once every 8 weeks in partial responders, only the patients receiving a dose of 90 mg of ustekinumab achieved the primary endpoint (69% of patients receiving 90 mg every 8 weeks versus 33% of those who continued with the same dose every 12 weeks, with a difference in response rate of 35%, \(p=0.004\)).

The ACCEPT study compared two biologic agents, ustekinumab and etanercept (an anti-TNF agent) for the treatment of psoriasis.\(^{17}\) The efficacy and safety of a crossover from etanercept to ustekinumab were also assessed after week 12. The efficacy of ustekinumab at dose 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period: 68% patients receiving 45 mg ustekinumab and 74% of patients receiving 90 mg ustekinumab, compared to 57% of patients receiving etanercept reached the endpoint (\(p=0.01\) and \(p<0.001\), respectively). After the crossover, 50% of patients who had no response to etanercept reached the primary endpoint with ustekinumab.

The PEARL trial confirmed the efficacy of ustekinumab in Taiwanese and Korean patients with moderate-to-severe psoriasis.\(^{18}\) At week 12, 67% of patients receiving ustekinumab (45 mg) versus 5% of patients under placebo achieved an improvement of ≥75% in psoriasis area and severity index. In the Japanese trial, 59% and 68% of patients receiving ustekinumab 45 and 90 mg achieved the primary endpoint, respectively, compared with 7% in the placebo group.\(^{19}\)
Psoriatic arthritis
Efficacy of ustekinumab for the treatment of active psoriatic arthritis was also demonstrated in randomized clinical trials. After a crossover Phase II trial revealed that ustekinumab significantly reduced signs and symptoms of psoriatic arthritis compared to placebo, the Phase III PSUMMIT 1 trial randomized 615 patients with active psoriatic arthritis to 45 mg ustekinumab, 90 mg ustekinumab, or placebo at week 0, 4, and every 12 weeks. The primary endpoint was an improvement of ≥20% in the American College of Rheumatology response criteria at week 24. These criteria measure improvement in tender or swollen joint in at least three of the following parameters: patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant. More patients who received ustekinumab (42% of patients with 45 mg dose, 50% of patients with 90 mg dose) achieved the primary endpoint when compared to placebo (23%; p<0.0001). Clinical responses were maintained at week 52.

The PSUMMIT 2 trial assessed the efficacy and safety of ustekinumab every 12 weeks in patients with active psoriatic arthritis who had failed to respond to conventional and/or biologic anti-TNF agents. Patients with and without methotrexate (n=155 and n=157, respectively), who were naïve to anti-TNF agents (n=132), or who had failed to respond to anti-TNF therapy (n=180) were included. More ustekinumab-treated patients (43.8% combined) than placebo-treated ones (20.2%) achieved the primary endpoint at week 24 (p<0.001). A sustained efficacy was observed in patients who received ustekinumab after previous treatment with ≥1 anti-TNF agent.

A subsequent study observed that ustekinumab 45 and 90 mg significantly inhibited radiographic progression of joint damage in patients with active psoriatic arthritis included in the PSUMMIT 1 and 2 trials.

Ustekinumab in CD
The Phase IIb CERTIFI trial evaluated the efficacy of ustekinumab in adults with moderate-to-severe active CD who had previously failed to respond to anti-TNF agents. The primary endpoint was clinical response (≥100 points reduction from baseline CD Activity Index [CDAI] score). At induction, 526 patients received a single IV ustekinumab infusion at doses of 1, 3, or 6 mg/kg versus placebo. The primary endpoint was reached in 36.6%, 34.1%, and 39.7% of cases receiving ustekinumab (for 1, 3, and 6 mg/kg ustekinumab, respectively), as compared with 23.5% for placebo (p=0.005 for the comparison with the 6 mg/kg group). There were no statistically significant differences in the rates of clinical remission (CDAI<150). During the maintenance phase, 145 patients with clinical response were re-randomized at week 8 to receive SC injections of ustekinumab 90 mg or placebo at weeks 8 and 16. Rates of clinical response and clinical remission were significantly increased with ustekinumab as compared with placebo (69.4% versus 42.5%, p<0.001 and 41.7% versus 27.4%, p=0.03, respectively) at week 22.

The approval of ustekinumab for the treatment of moderate-to-severe CD was based on data from three pivotal Phase III trials which showed that treatment with ustekinumab induced clinical response and maintained clinical remission in a significantly greater proportion of patients with moderate-to-severe active CD after 1-year therapy compared to placebo: two induction trials (UNITI-1 and -2) and a maintenance trial (IM-UNITI trial). The UNITI-1 trial included patients with CD who were refractory or intolerant to anti-TNF (n=741), and the UNITI-2 trial included patients with CD refractory or intolerant to conventional therapy, glucocorticoids, or immunomodulators (n=628). Patients were randomly assigned to receive a single IV dose of ustekinumab (130 mg), a weight-range-based dose of ustekinumab (6 mg/kg), or placebo. Clinical response at week 6 (decrease from baseline in CDAI score of ≥100 points or a CDAI score <150) was assessed. In both trials, those patients receiving ustekinumab had a significantly higher rate of response after 6 weeks than placebo: 34.3%, 33.7%, and 21.5%, respectively (p≤0.003) in UNITI-1 and 51.7%, 55.5%, and 28.7% respectively (p<0.001) in UNITI-2.

Patients who completed the induction phase and had a clinical response to ustekinumab (n=397) were included in the IM-UNITI trial. They were randomly assigned to receive SC maintenance injections of ustekinumab (90 mg either every 8 weeks or every 12 weeks) or placebo. After 44 weeks, more patients receiving ustekinumab were in remission (CDAI score <150) than those receiving placebo: 53.1% and 48.8% of patients receiving ustekinumab every 8 weeks or every 12 weeks, as compared with 35.9% of those receiving placebo (p=0.005 and p=0.04, respectively). The main results of this trial are summarized in Table 1.

A recent Cochrane review concluded that high-quality evidence suggests that ustekinumab, at an optimal dose of 6 mg/kg, is effective for induction of clinical remission and clinical improvement in patients with moderate-to-severe CD.

Apart from randomized clinical trials, retrospective studies have shown the clinical efficacy of ustekinumab in around two-thirds of patients of real-life cohorts consisting...
of patients who had failed to respond to anti-TNF agents.\(^{27,28}\)

Data on reduction of C-reactive protein or improvement of endoscopic lesions have also been obtained.\(^{29,30}\) Endoscopic (mucosal healing) or radiographic response was observed in >50% of patients with refractory CD in a retrospective study.\(^{31}\)

Moreover, ustekinumab appears to be highly effective in the treatment of the paradoxical psoriasis-like lesions induced by the use of anti-TNF agents in patients with CD.\(^{32-35}\) These are the most frequent dermatologic adverse effects in CD patients receiving anti-TNF agents.

### Ustekinumab in other immune-related diseases

Even though the IL-12 family of cytokines is strongly implicated in the pathogenesis of multiple sclerosis, a Phase II trial including 249 patients did not show efficacy in relapsing–remitting multiple sclerosis.\(^{36}\) Although it was well tolerated, ustekinumab did not reduce the cumulative number of gadolinium-enhancing T1-weighted lesions. It has been postulated that this lack of clinical efficacy could be related to the inclusion of patients with advanced disease in this clinical trial.\(^{37}\)

Pyoderma gangrenosum is a neutrophilic dermatitis characterized by cutaneous ulceration. It is believed that IL-23 is involved in its pathogenesis, as this cytokine promotes inflammation via IL-17 production and neutrophil recruitment. Several case reports have described the use of ustekinumab in treatment of this condition, including a case of peristomal pyoderma in a patient with CD.\(^{38-42}\) However, there is still lack of specific trials to assess the efficacy, appropriate dosing, and safety of ustekinumab for this indication.

### Safety and tolerability of ustekinumab

Infections

Most of the data on safety have been collected in patients with psoriasis, in which ustekinumab was first administered. Long-term follow-up studies on the use of ustekinumab in patients with moderate-to-severe psoriasis analyzed the safety profile in >3,000 patients and revealed a safe profile of the drug.\(^{43-46}\) Common adverse effects were headache, nasopharyngitis, upper respiratory tract infections, sinusitis, fatigue, pruritus, back pain, and arthralgia. No cases of tuberculosis or other severe infections were described.

The PSOLAR observational registry evaluated the risk of serious infections in 12,093 patients with psoriasis receiving conventional or biologic agents.\(^{47,48}\) Ustekinumab was not associated with an increased risk of serious infections compared with the use of non-biologic therapies, and presented the lowest rate of serious infections compared to other biologic agents (rates of serious infections of 0.83, 1.47, 1.97, and 2.49 per 100 patient-years in the ustekinumab, etanercept, adalimumab, and infliximab cohorts, respectively). Furthermore, in a recently published systematic review and

---

### Table I Phase III randomized controlled trial with ustekinumab in patients with moderate-to-severe Crohn’s disease

<table>
<thead>
<tr>
<th>Phase III trials</th>
<th>No. patients</th>
<th>Inclusion criteria</th>
<th>Randomization</th>
<th>Primary endpoint</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNITI-1</td>
<td>741</td>
<td>Patients with primary or secondary nonresponse to anti-TNF or unacceptable side effects versus placebo</td>
<td>1:1:1 Ratio</td>
<td>Clinical response at week 6 (decrease from baseline in the CDAI score of ≥100 points or a CDAI score &lt;150)</td>
<td>The rates of response at week 6 among patients receiving IV ustekinumab at a dose of either 130 mg or 6 mg/kg were significantly higher than the rates among patients receiving placebo: • UNITI-1: 34.3%, 33.7%, and 21.5%, respectively (p=0.003 for both comparisons with placebo) • UNITI-2: 51.7%, 55.5%, and 28.7%, respectively (p&lt;0.001 for both doses)</td>
</tr>
<tr>
<td>UNITI-2</td>
<td>628</td>
<td>Patients in whom conventional therapy had failed or led to unacceptable side effects</td>
<td>Placebo</td>
<td>Remission at week 44 (CDAI score &lt;150)</td>
<td>53.1% of patients receiving maintenance doses of ustekinumab every 8 weeks, and 48.8% of patients receiving maintenance doses of ustekinumab every 12 weeks were in remission at week 44, as compared with 35.9% of those receiving placebo (p=0.005 and p=0.04, respectively)</td>
</tr>
<tr>
<td>IM-UNITI</td>
<td>397</td>
<td>Patients who completed the induction trials and had a clinical response to ustekinumab</td>
<td>1:1:1 Ratio</td>
<td>• SC injections of 90 mg of ustekinumab every 8 weeks • SC injection of 90 mg of ustekinumab every 12 weeks • Placebo</td>
<td>• Placebo</td>
</tr>
</tbody>
</table>
meta-analysis of 27 randomized trials in 10,629 patients with moderate-to-severe psoriasis, ustekinumab was the only biologic agent that did not show increased risk of adverse effects, when compared to placebo in a short-term follow-up.49

The most common non-gastrointestinal adverse effects in patients with CD in the CERTIFI trial included headache, arthralgia, and nasopharyngitis.28 Infection rates were similar in patients receiving ustekinumab as well as placebo. In the UNITI-1, UNITI-2, and IM-UNITI trials, 13 patients developed serious infections: 2.3% of patients in the group receiving ustekinumab every 8 weeks, 5.3% in the group receiving ustekinumab every 12 weeks, and 2.3% in the placebo group.25 The main adverse events in the UNITI trials are presented in Table 2.

A systematic review and meta-analysis evaluated the safety profile of the different available biologic agents in patients with CD.50 Ten randomized clinical trials met the inclusion criteria with the different drugs, and did not reveal significant differences in the safety profile of adalimumab vedolizumab, certolizumab pegol, ustekinumab, and placebo.24,51–59

Malignancies

Regarding the risk of malignancies, Phase II and III trials on psoriatic patients are reassuring about the long-term safety of ustekinumab.44 Three of four malignancies reported in ustekinumab-treated patients and two of the three malignancies reported in placebo-treated patients were non-melanoma skin cancers (NMSCs). In the long-term follow-up studies of ustekinumab on psoriasis, the pattern of NMSC was similar to that observed in psoriasis clinical trials of other biologics.43–46 The rates of malignancies other than NMSC in ustekinumab-treated patients were comparable with the expected rates in the general population.

In the CERTIFI trial in patients with CD, one case of NMSC developed in a patient receiving ustekinumab.52 Eight cases of NMSC were reported in the IM-UNITI trial, with three of them in patients receiving placebo.25 One patient receiving ustekinumab every 12 weeks developed a metastatic adenocarcinoma in the small bowel, and a carcinoid tumor was found incidentally in the resected bowel.

Other diseases

No cases of demyelination were described in the long-term studies on ustekinumab in psoriasis.41–46 However, a case of demyelination in a patient receiving ustekinumab for CD has been reported.60

Despite the concerns about an increased risk of major adverse cardiovascular events in patients under ustekinumab for psoriasis, a recently published systematic review and meta-analysis of 38 randomized clinical trials did not find any association.61

The impact of ustekinumab on asthma, atopic dermatitis, and seasonal allergies was also evaluated in the long-term follow-up of PHOENIX 1 and 2 trials, due to its potential to block differentiation of Th1 cells, which could lead to a greater polarization of immune responses toward a Th2 phenotype, but no negative effects were observed.43

### Immunogenicity

The incidence of injection-site reactions to ustekinumab was low in psoriatic patients.15,16 These reactions were generally mild, and most of them did not appear to be allergic or hypersensitivity reactions. No cases of anaphylaxia or serum sickness-like reactions were reported during the study period. Immunogenicity rates remained low through 5-year follow-up, with detection of antibodies in 5.2% of patients.45

In patients with CD, rates of antibodies to ustekinumab across the Phase III trials were low, ranging from 3.8% to 5.4%; also, the presence of antibodies was not associated with the occurrence of injection site reactions.25 The correlation of ustekinumab trough concentrations with clinical, biologic, and endoscopic responses in patients with CD-refractory anti-TNF has only been analyzed in a cohort of 62 patients.62

---

**Table 2** Adverse events in Phase III randomized controlled trials with ustekinumab in patients with moderate-to-severe Crohn’s disease

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>In patients receiving placebo (%)</th>
<th>In patients receiving ustekinumab (any dose) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common adverse events</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>41 (7)</td>
<td>98 (8)</td>
</tr>
<tr>
<td>Headache</td>
<td>51 (9)</td>
<td>101 (9)</td>
</tr>
<tr>
<td>Nausea</td>
<td>32 (5)</td>
<td>65 (6)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>35 (6)</td>
<td>65 (6)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>33 (6)</td>
<td>78 (7)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>36 (6)</td>
<td>61 (5)</td>
</tr>
<tr>
<td>Crohn’s disease event</td>
<td>53 (9)</td>
<td>66 (6)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>23 (4)</td>
<td>36 (3)</td>
</tr>
<tr>
<td><strong>Infectious events</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>172 (29)</td>
<td>321 (27)</td>
</tr>
<tr>
<td>Serious</td>
<td>9 (2)</td>
<td>24 (2)</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td>47 (8)</td>
<td>75 (6)</td>
</tr>
<tr>
<td>Infusion or injection-site reactions</td>
<td>12 (2)</td>
<td>40 (3)</td>
</tr>
</tbody>
</table>

**Notes:** Data from Feagan et al.35 Adverse effects through week 8 in UNITI-1 and UNITI-2 and through week 44 in IM-UNITI. *Number of patients receiving placebo: n=245 in UNITI-1; n=208 in UNITI-2; n=133 in IM-UNITI. *Number of patients receiving ustekinumab (any dose): n=495 in UNITI-1; n=419 in UNITI-2; n=263 in IM-UNITI. The common adverse events were reported by at least 5% of the patients in any group. UNITI-1 and -2, two induction trials; IM-UNITI, maintenance trial.
Patients with concentrations >4.5 μg/mL presented better clinical and endoscopic outcomes, but larger studies are required to confirm the optimal therapeutic concentration.

Special populations
There are insufficient data to recommend ustekinumab in pregnancy and breast feeding. Current evidence does not indicate an increase rate of congenital malformations in children born from mothers using ustekinumab during pregnancy in patients with dermatologic or rheumatic disease.63,64 No data are available regarding its use while breast feeding. Regarding CD, no meta-analysis reports on the safety of ustekinumab during pregnancy are available. Only two case reports of patients with CD under maintenance therapy with ustekinumab before pregnancy have been reported.65,66 The patients maintained remission of CD, and no adverse effects were observed during pregnancy and they gave birth to healthy children.

Minimizing corticoid exposure is even more important in pediatric CD populations, owing to their negative effects on growth. The administration of ustekinumab has been reported in some cases of pediatric CD refractory to immunomodulators and anti-TNF agents with the aim of achieving mucosal healing, and no safety issues have been described.67–69

Elderly patients are another subgroup of patients with higher risks of adverse events after the administration of systemic treatments because of the presence of comorbidities and/or lower treatment adherence. Available studies do not show an increased risk of developing complications in patients older than 65 years with psoriasis.70,71

Conclusion
Ustekinumab is a fully human monoclonal antibody directed against the p40 subunit of IL-12 and IL-23 that has been exhaustively investigated for the treatment of psoriasis and psoriatic arthritis, where it appears to be safe and effective.

It has been recently approved for its use in patients with CD. Current evidence in CD shows positive results of ustekinumab in patients refractory to anti-TNF agents, with significantly increased rates of clinical response and remission compared to placebo. In addition, ustekinumab has a favorable safety profile, as it does not increase the risk of infections and malignancies, and shows low rates of development of anti-drug antibodies. Moreover, ustekinumab is also effective for the treatment of psoriasis-like paradoxical lesions induced by anti-TNF agents.

However, data on perianal disease or extraintestinal manifestations of CD, as well as long-term data on safety and clinical/endoscopic efficacy should be obtained in the coming years.

Future perspectives
It is not clear whether the efficacy of ustekinumab is driven by the inhibition of IL-12 or IL-23. Moreover, inhibition of the IL-12 pathway could have potential risks in tumor immune surveillance and host defense against intracellular pathogens.

Several new agents that induce a selective blockade of IL-23 are currently being developed. Risankinumab is a humanized monoclonal antibody that selectively targets the specific p19 subunit of IL-23.72 Recently published Phase II studies on the use of risankinumab for the treatment of patients with psoriasis and CD have shown promising results.73,74 The results of Phase III trials will determine the efficacy and safety profile of this new molecule.

Disclosure
The authors report no conflicts of interest in this work.

References
6. Cua DJ, Sherlock J, Chen Y, et al. IL-12 and IL-23 cytokines: development of anti-drug antibodies. Moreover, inhibition of the IL-12 pathway could have potential risks in tumor immune surveillance and host defense against intracellular pathogens.


